QNTM
Quantum BioPharma Ltd.
Drug Manufacturers - Specialty & Generic
Market Cap$22M
5Y Perf.-95.7%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
QNTM vs MNMD vs CMPS vs ATAI vs CYBN
Revenue, margins, valuation, and 5-year total return — side by side.
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-63.5%
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$952M
5Y Perf.-74.0%
ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$969M
5Y Perf.-78.2%
CYBN
Cybin Inc.
Biotechnology
Market Cap$304M
5Y Perf.-91.4%
QNTM vs MNMD vs CMPS vs ATAI vs CYBN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | QNTM | MNMD | CMPS | ATAI | CYBN |
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology | Medical - Care Facilities | Medical - Pharmaceuticals | Biotechnology |
| Market Cap | $22M | $2.04B | $952M | $969M | $304M |
| Revenue (TTM) | $0.00 | $0.00 | $0.00 | $3M | $0.00 |
| Net Income (TTM) | $-31M | $-238M | $-288M | $-154M | $-123M |
| Gross Margin | — | — | — | -259.1% | — |
| Operating Margin | — | — | — | -34.6% | — |
| Total Debt | $2M | $0.00 | $21M | $25M | $0.00 |
| Cash & Equiv. | $2M | $258M | $150M | $18M | $135M |
QNTM vs MNMD vs CMPS vs ATAI vs CYBN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
QNTM
MNMD
CMPS
ATAI
CYBN
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Quantum BioPharma L… (QNTM) | 100 | 4.3 | -95.7% |
| Mind Medicine (Mind… (MNMD) | 100 | 36.5 | -63.5% |
| COMPASS Pathways plc (CMPS) | 100 | 26.0 | -74.0% |
| Atai Beckley N.V (ATAI) | 100 | 21.8 | -78.2% |
| Cybin Inc. (CYBN) | 100 | 8.6 | -91.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: QNTM vs MNMD vs CMPS vs ATAI vs CYBN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CYBN leads in 2 of 6 categories (5-stock set), making it the strongest pick for profitability and margin quality and operational efficiency and capital deployment. Quantum BioPharma Ltd. is the stronger pick specifically for capital preservation and lower volatility. MNMD and ATAI also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
QNTM
Quantum BioPharma Ltd.
The Income Pick
QNTM is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- beta 0.97
- Lower volatility, beta 0.97, Low D/E 36.8%, current ratio 1.07x
- Beta 0.97, current ratio 1.07x
- Beta 0.97 vs MNMD's 1.63
Best for: income & stability and sleep-well-at-night
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD ranks third and is worth considering specifically for long-term compounding.
- 5.1% 10Y total return vs ATAI's -47.6%
- +220.3% vs QNTM's -44.2%
Best for: long-term compounding
CMPS
COMPASS Pathways plc
The Healthcare Pick
Among these 5 stocks, CMPS doesn't own a clear edge in any measured category.
Best for: healthcare exposure
ATAI
Atai Beckley N.V
The Growth Leader
ATAI is the clearest fit if your priority is growth.
- -1.9% revenue growth vs MNMD's -96.9%
Best for: growth
CYBN
Cybin Inc.
The Growth Play
CYBN carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 93.5%
- 3.2% margin vs ATAI's -51.1%
- -58.3% ROA vs QNTM's -222.9%, ROIC -115.8% vs -222.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATAI | -1.9% revenue growth vs MNMD's -96.9% |
| Quality / Margins | CYBN | 3.2% margin vs ATAI's -51.1% |
| Stability / Safety | QNTM | Beta 0.97 vs MNMD's 1.63 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | MNMD | +220.3% vs QNTM's -44.2% |
| Efficiency (ROA) | CYBN | -58.3% ROA vs QNTM's -222.9%, ROIC -115.8% vs -222.1% |
QNTM vs MNMD vs CMPS vs ATAI vs CYBN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2024
Segment breakdown not available.
QNTM vs MNMD vs CMPS vs ATAI vs CYBN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLQNTMLAGGINGCYBN
Who Leads Where
QNTM leads in 1 of 6 categories
MNMD leads 1 • CMPS leads 0 • ATAI leads 0 • CYBN leads 0 • 3 tied
Explore the data ↓CYBNCybin Inc.
0leads
ATAIAtai Beckley N.V
0leads
CMPSCOMPASS Pathways plc
0leads
MNMDMind Medicine (MindMe…
1leads
QNTMQuantum BioPharma Ltd.
1leads
6 Total Categories
CATEGORYLEADERvs MNMDvs CMPSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
QNTM1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
QNTM leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATAI and CYBN operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | QNTMQuantum BioPharma… | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $0 | $3M | $0 |
| EBITDAEarnings before interest/tax | -$4M | -$191M | -$179M | -$103M | -$147M |
| Net IncomeAfter-tax profit | -$31M | -$238M | -$288M | -$154M | -$123M |
| Free Cash FlowCash after capex | -$6M | -$174M | -$157M | -$90M | -$106M |
| Gross MarginGross profit ÷ Revenue | — | — | — | -2.6% | — |
| Operating MarginEBIT ÷ Revenue | — | — | — | -34.6% | — |
| Net MarginNet income ÷ Revenue | — | — | — | -51.1% | — |
| FCF MarginFCF ÷ Revenue | — | — | — | -29.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | +17.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +60.4% | -163.0% | -58.7% | -75.0% | -8.2% |
QNTM leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — QNTM and CYBN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | QNTMQuantum BioPharma… | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $22M | $2.0B | $952M | $969M | $304M |
| Enterprise ValueMkt cap + debt − cash | $22M | $1.8B | $824M | $976M | $205M |
| Trailing P/EPrice ÷ TTM EPS | -0.60x | -10.04x | -3.22x | -4.33x | -13.66x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | — | 3145.98x | — |
| Price / BookPrice ÷ Book value/share | 3.15x | 5.56x | — | 5.54x | 6.52x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Evenly matched — QNTM and CYBN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — MNMD and CYBN each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
CYBN delivers a -81.0% return on equity — every $100 of shareholder capital generates $-81 in annual profit, vs $-9 for QNTM. ATAI carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to QNTM's 0.37x. On the Piotroski fundamental quality scale (0–9), MNMD scores 3/9 vs QNTM's 1/9, reflecting mixed financial health.
| Metric | QNTMQuantum BioPharma… | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -9.4% | -102.5% | -3.4% | -96.4% | -81.0% |
| ROA (TTM)Return on assets | -2.2% | -70.7% | -106.8% | -64.3% | -58.3% |
| ROICReturn on invested capital | -2.2% | -3.9% | — | -45.0% | -115.8% |
| ROCEReturn on capital employed | -197.0% | -52.2% | -2.5% | -50.4% | -54.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 | 2 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.37x | — | — | 0.21x | — |
| Net DebtTotal debt minus cash | -$29,093 | -$258M | -$129M | $7M | -$135M |
| Cash & Equiv.Liquid assets | $2M | $258M | $150M | $18M | $135M |
| Total DebtShort + long-term debt | $2M | $0 | $21M | $25M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -54.04x | -21.81x | -52.40x | -68.93x | — |
Evenly matched — MNMD and CYBN each lead in 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNMD five years ago would be worth $4,493 today (with dividends reinvested), compared to $475 for QNTM. Over the past 12 months, MNMD leads with a +220.3% total return vs QNTM's -44.2%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs QNTM's -60.5% — a key indicator of consistent wealth creation.
| Metric | QNTMQuantum BioPharma… | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -30.4% | +51.7% | +51.3% | +4.1% | -26.4% |
| 1-Year ReturnPast 12 months | -44.2% | +220.3% | +163.6% | +187.9% | -8.1% |
| 3-Year ReturnCumulative with dividends | -93.8% | +510.3% | +17.1% | +100.5% | -49.8% |
| 5-Year ReturnCumulative with dividends | -95.2% | -55.1% | -72.3% | -79.7% | -90.2% |
| 10-Year ReturnCumulative with dividends | -99.6% | +512.1% | -65.8% | -47.6% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -60.5% | +82.7% | +5.4% | +26.1% | -20.5% |
MNMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — QNTM and MNMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
QNTM is the less volatile stock with a 0.97 beta — it tends to amplify market swings less than MNMD's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs QNTM's 12.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | QNTMQuantum BioPharma… | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.97x | 1.63x | 1.28x | 1.44x | 1.49x |
| 52-Week HighHighest price in past year | $38.25 | $21.09 | $10.21 | $6.75 | $9.83 |
| 52-Week LowLowest price in past year | $2.07 | $6.03 | $2.25 | $1.29 | $5.50 |
| % of 52W HighCurrent price vs 52-week peak | +12.8% | +98.1% | +97.1% | +59.7% | +62.0% |
| RSI (14)Momentum oscillator 0–100 | 58.4 | 64.9 | 63.4 | 47.1 | 35.5 |
| Avg Volume (50D)Average daily shares traded | 496K | 779K | 3.6M | 5.8M | 292K |
Evenly matched — QNTM and MNMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MNMD as "Buy", CMPS as "Buy", ATAI as "Buy", CYBN as "Buy". Consensus price targets imply 197.8% upside for ATAI (target: $12) vs -3.3% for MNMD (target: $20).
| Metric | QNTMQuantum BioPharma… | MNMDMind Medicine (Mi… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $20.00 | $18.00 | $12.00 | — |
| # AnalystsCovering analysts | — | 1 | 13 | 4 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
QNTM leads in 1 of 6 categories (Income & Cash Flow). MNMD leads in 1 (Total Returns). 3 tied.
Best OverallQuantum BioPharma Ltd. (QNTM)Leads 1 of 6 categories
Loading custom metrics...
QNTM vs MNMD vs CMPS vs ATAI vs CYBN: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is QNTM or MNMD or CMPS or ATAI or CYBN a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — QNTM or MNMD or CMPS or ATAI or CYBN?
Over the past 5 years, Mind Medicine (MindMed) Inc.
(MNMD) delivered a total return of -55. 1%, compared to -95. 2% for Quantum BioPharma Ltd. (QNTM). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — QNTM or MNMD or CMPS or ATAI or CYBN?
By beta (market sensitivity over 5 years), Quantum BioPharma Ltd.
(QNTM) is the lower-risk stock at 0. 97β versus Mind Medicine (MindMed) Inc. 's 1. 63β — meaning MNMD is approximately 68% more volatile than QNTM relative to the S&P 500. On balance sheet safety, Atai Beckley N. V (ATAI) carries a lower debt/equity ratio of 21% versus 37% for Quantum BioPharma Ltd. — giving it more financial flexibility in a downturn.
04Which is growing faster — QNTM or MNMD or CMPS or ATAI or CYBN?
On earnings-per-share growth, the picture is similar: Cybin Inc.
grew EPS 93. 5% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — QNTM or MNMD or CMPS or ATAI or CYBN?
Quantum BioPharma Ltd.
(QNTM) is the more profitable company, earning 0. 0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QNTM leads at 0. 0% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — QNTM or MNMD or CMPS or ATAI or CYBN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is QNTM or MNMD or CMPS or ATAI or CYBN better for a retirement portfolio?
For long-horizon retirement investors, Quantum BioPharma Ltd.
(QNTM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 97)). Both have compounded well over 10 years (QNTM: -99. 6%, CYBN: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between QNTM and MNMD and CMPS and ATAI and CYBN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.